CCT020312
CCT020312 is a potent and selective EIF2AK3 Activator. CCT020312 modulates the biological activity of EIF2AK3. CCT020312 sensitizes cancer cells with defective taxane-induced EIF2A phosphorylation to paclitaxel treatment. CCT020312 is a novel small molecule chemical tool for the selective activation of EIF2A-mediated translation control with utility for proof-of-concept applications in EIF2A-centered therapeutic approaches, and as a chemical starting point for pathway selective agent development. CCT020312 is potent, and EIF2AK3 selective agent and can act as a sensitizer to chemotherapy-associated stresses as elicited by taxanes.
仅供研究使用。 我们不向患者出售。
化学信息
| 名称 | CCT020312 |
|---|---|
| Iupac 化学名称 | 6-Bromo-3-[5-(4-bromo-phenyl)-1-(3-diethylamino-propionyl)-4,5-dihydro-1H-pyrazol-3-yl]-4-phenyl-1H-quinolin-2-one |
| 同义词 | CCT020312; CCT-020312; CCT 020312. |
| 英文同义词 | CCT020312; CCT-020312; CCT 020312. |
| 分子式 | C31H30Br2N4O2 |
| 分子量 | 650.40 |
| Smile | O=C1NC2=C(C=C(Br)C=C2)C(C3=CC=CC=C3)=C1C4=NN(C(CCN(CC)CC)=O)C(C5=CC=C(Br)C=C5)C4 |
| InChiKey | OAXDKXMGESZLKV-UHFFFAOYSA-N |
| InChi | InChI=1S/C31H30Br2N4O2/c1-3-36(4-2)17-16-28(38)37-27(20-10-12-22(32)13-11-20)19-26(35-37)30-29(21-8-6-5-7-9-21)24-18-23(33)14-15-25(24)34-31(30)39/h5-15,18,27H,3-4,16-17,19H2,1-2H3,(H,34,39) |
| Cas号 | 324759-76-4 |
| 相关CAS号 |
订购信息
| 包装 | 价格 | 库存 | 纯度 | 备货期 |
|---|---|---|---|---|
| 大货 | 询价 | 询价 | 询价 |
| 外观性状 | 固体粉末 |
|---|---|
| 纯度 | 98% Min. |
| 存储 | 短期（几天到几周）为0-4摄氏度，长期（几个月）为-20摄氏度 |
| 可溶性 | 溶于DMSO |
| 处理方式 | |
| 运输条件 | 作为非危险化学品在环境温度下装运。这种产品在正常运输和海关工作期间可以稳定几周. |
| 海关编码 |
| Targets | |
|---|---|
| Mechanism | |
| Cell study | |
| Animal study | |
| Clinical study |
1: Stockwell SR, Platt G, Barrie SE, Zoumpoulidou G, Te Poele RH, Aherne GW,
Wilson SC, Sheldrake P, McDonald E, Venet M, Soudy C, Elustondo F, Rigoreau L,
Blagg J, Workman P, Garrett MD, Mittnacht S. Mechanism-based screen for G1/S
checkpoint activators identifies a selective activator of EIF2AK3/PERK
signalling. PLoS One. 2012;7(1):e28568. doi: 10.1371/journal.pone.0028568. PubMed
PMID: 22253692; PubMed Central PMCID: PMC3257223.
2: Bruch J, Xu H, Rösler TW, De Andrade A, Kuhn PH, Lichtenthaler SF, Arzberger
T, Winklhofer KF, Müller U, Höglinger GU. PERK activation mitigates tau pathology
in vitro and in vivo. EMBO Mol Med. 2017 Feb 1. pii: e201606664. doi:
10.15252/emmm.201606664. [Epub ahead of print] PubMed PMID: 28148553.
